WhaleCreep

Avidity Partners Management LP 13F holdings, Q1 2026

Hedge fundSEC filingsCompare with another fundHoldings as of 2026-03-31, filed 2026-05-28

Avidity Partners Management LP disclosed 45 US equity positions worth $493.8m in its Q1 2026 13F filing. Its largest position is DNTH at 35.8% of the reported book, followed by CGON and ORKA. Versus Q4 2025 it opened 21 new positions, added to 11, reduced 10 and exited 15.

$494m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
45
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
35.8%
Largest position
The largest single position as a share of the reported equity book.
82.3%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
6
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2025: 21 new, 11 added, 10 reduced, 15 exited

45 rows
DNTH DIANTHUS THERAPEUTICS INCHealthcare35.8%$177m2.10m0.0%held
CGON CG ONCOLOGY INCHealthcare17.7%$87.2m1.29m−12%reduced
ORKA ORUKA THERAPEUTICS INCHealthcare7.6%$37.3m760,424+15%added
CATX PERSPECTIVE THERAPEUTICS INC–5.1%$25.2m6.05m+88%added
JBIO JADE BIOSCIENCES INCHealthcare4.0%$19.7m1.40m0.0%held
ELVN ENLIVEN THERAPEUTICS INCHealthcare3.2%$15.7m400,000+185%added
TEVA TEVA PHARMACEUTICAL INDS LTDHealthcare2.7%$13.6m450,100+7.9%added
CNTX CONTEXT THERAPEUTICS INC–2.7%$13.1m5.00m−9.2%reduced
RGEN REPLIGEN CORPHealthcare1.9%$9.2m77,800+55%added
PVLA PALVELLA THERAPEUTICS INC NEHealthcare1.8%$8.7m70,000+263%added
MDT Medtronic PlcHealthcare1.8%$8.7m100,000−7.1%reduced
VIR VIR BIOTECHNOLOGY INCHealthcare1.7%$8.5m950,000–new
AKTS AKTIS ONCOLOGY INCHealthcare1.7%$8.4m468,566–new
IMUX IMMUNIC INCHealthcare1.5%$7.4m6.70m+43%added
DXCM DEXCOM INCHealthcare1.1%$5.7m90,000–new
EHC ENCOMPASS HEALTH CORPHealthcare0.8%$4.1m42,000+33%added
BSX BOSTON SCIENTIFIC CORPHealthcare0.8%$3.8m60,000−48%reduced
TENX TENAX THERAPEUTICS INC–0.7%$3.5m215,934–new
GILD GILEAD SCIENCES INCHealthcare0.6%$2.8m20,000–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare0.6%$2.8m249,390+21%added
KPTI KARYOPHARM THERAPEUTICS INC–0.5%$2.6m463,741+245%added
CNC CENTENE CORP DELHealthcare0.5%$2.3m70,000−41%reduced
MSLE SATELLOS BIOSCIENCE INC–0.4%$2.2m387,769–new
SCYX SCYNEXIS INC–0.4%$1.9m2.08m0.0%held
NTRA NATERA INCHealthcare0.4%$1.8m9,000−24%reduced
ICLR ICON PLCHealthcare0.4%$1.8m16,000−52%reduced
KVUE KENVUE INCConsumer Defensive0.3%$1.7m100,000−57%reduced
CRVS CORVUS PHARMACEUTICALS INCHealthcare0.3%$1.7m115,000–new
HIMS HIMS & HERS HEALTH INCHealthcare0.3%$1.6m75,000–new
RVMD REVOLUTION MEDICINES INCHealthcare0.3%$1.5m15,000–new
GPCR STRUCTURE THERAPEUTICS INCHealthcare0.3%$1.4m30,000–new
GMAB GENMAB A/SHealthcare0.3%$1.3m50,000−46%reduced
CORT CORCEPT THERAPEUTICS INCHealthcare0.2%$1.2m30,000+36%added
TEM TEMPUS AI INCHealthcare0.2%$1.1m25,000–new
ABVX ABIVAX SAHealthcare0.2%$1.1m10,000–new
UNH UNITEDHEALTH GROUP INCHealthcare0.2%$1.0m3,800–new
NTLA INTELLIA THERAPEUTICS INCHealthcare0.2%$962k75,000–new
ODD ODDITY TECH LTDConsumer Defensive0.2%$937k70,000–new
MLTX MOONLAKE IMMUNOTHERAPEUTICSHealthcare0.2%$932k50,000–new
PTON PELOTON INTERACTIVE INCConsumer Cyclical0.2%$858k200,000–new
AVR ANTERIS TECHNOLOGIES GLOBALHealthcare0.2%$833k150,000–new
ABUS ARBUTUS BIOPHARMA CORPHealthcare0.1%$563k125,000–new
BBOT BRIDGEBIO ONCOLOGY THERAPEUTHealthcare0.08%$392k43,853–new
ACAD ACADIA PHARMACEUTICALS INCHealthcare0.06%$289k12,967−88%reduced
TRVI TREVI THERAPEUTICS INCHealthcare0.02%$79.5k6,660–new

Exited since Q4 2025

15 rows
ALNY ALNYLAM PHARMACEUTICALS INC2.4%$8.4m
MCK MCKESSON CORP2.3%$7.8m
A AGILENT TECHNOLOGIES INC1.6%$5.6m
PFE PFIZER INC1.5%$5.1m
DHR DANAHER CORP DEL1.1%$3.9m
TMO THERMO FISHER SCIENTIFIC INC1.1%$3.9m
NVO NOVO-NORDISK A S1.0%$3.4m
CI THE CIGNA GROUP0.9%$3.2m
COR CENCORA INC0.9%$3.2m
INSM INSMED INC0.9%$3.1m
WAT WATERS CORP0.9%$3.1m
ACHC ACADIA HEALTHCARE COMPANY IN0.7%$2.4m
ITGR INTEGER HLDGS CORP0.7%$2.3m
HQY HEALTHEQUITY INC0.4%$1.5m
IQV IQVIA HLDGS INC0.3%$992k

Sector mix

  • Healthcare89.5%
  • Unclassified9.8%
  • Consumer Defensive0.5%
  • Consumer Cyclical0.2%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters